← Patent-cliff monitor small molecule AYVAKIT AVAPRITINIB
Loss of exclusivity April 2040 latest FDA-listed patent expiry
Drug detail Brand name AYVAKIT Active ingredient AVAPRITINIB Strength 25MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval June 2021 Marketing status RX
Listed patents Patent Expires Type 12252494 April 2040 use U-3506 11999744 April 2040 use U-3506 11964980 April 2040 substance, product 11827642 October 2034 substance, product 9944651 October 2034 substance, product 9200002 October 2034 substance, product 9994575 October 2034 substance, product
Regulatory exclusivity Code Expires ODE-434 May 2030 ODE-356 June 2028 ODE-366 January 2027 I-912 May 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.